Connor Clark & Lunn Investment Management Ltd. Acquires 12,245 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Connor Clark & Lunn Investment Management Ltd. grew its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 114.4% during the third quarter, HoldingsChannel reports. The firm owned 22,949 shares of the specialty pharmaceutical company’s stock after buying an additional 12,245 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in KalVista Pharmaceuticals were worth $266,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KALV. Quest Partners LLC bought a new position in KalVista Pharmaceuticals during the third quarter worth about $175,000. Emerald Advisers LLC increased its position in KalVista Pharmaceuticals by 29.8% in the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock worth $9,681,000 after purchasing an additional 192,091 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in shares of KalVista Pharmaceuticals by 23.0% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after buying an additional 121,615 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after purchasing an additional 3,328 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of KalVista Pharmaceuticals during the 3rd quarter worth about $153,000.

KalVista Pharmaceuticals Trading Down 0.3 %

KALV opened at $10.06 on Monday. The company’s 50 day moving average is $10.95 and its 200-day moving average is $11.90. The company has a market cap of $434.79 million, a P/E ratio of -2.85 and a beta of 0.92. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.39 and a 1-year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. On average, equities analysts forecast that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Insider Transactions at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the sale, the insider now owns 94,199 shares in the company, valued at $872,282.74. This trade represents a 7.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,352 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the completion of the sale, the chief executive officer now owns 250,800 shares in the company, valued at approximately $3,057,252. The trade was a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,016 shares of company stock valued at $319,344 in the last quarter. 10.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

KALV has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday, October 7th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).